The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Objectives. Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and metformin (MET) have markedly antiobesity effects in overweight/obese polycystic ovary syndrome (PCOS) patients. However, there was no literature to compare the antiobesity effects of these two medicines. Therefore, a systematic review and meta-analysis were conducted in our present study to evaluate the antiobesity effects of GLP-1RAs either as monotherapy or combined with MET in comparison with MET alone in overweight/obese PCOS patients. Methods. All randomized controlled trials (RCTs) which reported the efficacy of GLP-1RAs and MET in overweight/obese PCOS patients in Medline (from Pubmed), Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus databases were independently searched by two reviewers. The random-effect model was used to pool data extracted from the included literature. The weighted mean difference (WMD) and 95% confidence interval (CI) were used to present the meta-analysis results (PROSPERO registration number: CRD42020173199). Results. A total of eight eligible RCTs were finally enrolled in our meta-analysis from the 587 retrieved literature. The results showed that GLP-1RAs alone or combined with MET was associated with a greater weight loss (N = 318, WMD = −2.61, 95% CI: −3.51 to −1.72, P ≤ 0.001 , I2 = 77.5%), more obvious reduction of waist circumference (N = 276, WMD = −3.46, 95% CI: −4.36 to −2.56, P ≤ 0.001 , I2 = 0.0%), and body mass index (BMI) (N = 318, WMD = −0.93, 95% CI: −1.60 to −0.26, P = 0.007 , I2 = 84.9%) in overweight/obese PCOS patients when compared with MET alone. Further sensitivity analysis demonstrated that the meta-analysis results of the efficacy differences in terms of body weight, waist circumference, and BMI were relatively stable and reliable. Conclusion. Our meta-analysis demonstrated that the antiobesity effect of GLP-1RAs alone or combined with MET was superior to MET alone in terms of weight loss, the reduction of waist circumference, and BMI. More large-scale, high-quality RCTs are needed to further confirm these results in PCOS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Lifestyle changes in women with polycystic ovary syndrome
Lim, S. S., Hutchison, S. K., Van Ryswyk, E., Norman, R. J., Teede, H. J., & Moran, L. J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007506.pub4 · Cited by 725
Yildiz, B. O., Bozdag, G., Yapici, Z., Esinler, I., & Yarali, H. (2012) · Human Reproduction · doi:10.1093/humrep/des232 · Cited by 704
The polycystic ovary syndrome: a position statement from the European Society of Endocrinology
Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., Kelestimur, F., Macut, D., Micic, D., Pasquali, R., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0253 · Cited by 676
Moran, L. J., Noakes, M., Clifton, P. M., Tomlinson, L., & Norman, R. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020815 · Cited by 530
Carmina, E., & Lobo, R. A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.6.5803 · Cited by 528
Moran, L. J., Pasquali, R., Teede, H. J., Hoeger, K. M., & Norman, R. J. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.09.018 · Cited by 444
Metformin: Mechanisms in Human Obesity and Weight Loss
Yerevanian, A., & Soukas, A. A. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00335-3 · Cited by 414 · cited 1×
“*e antiobesity mechanisms of MET are related to various aspects, including the decrease in hepatic gluconeogenesis and insulin synthesis, the inhibition of the hypothalamic appetite regulatory center, and changes in the gut microbiome [33].”
BackgroundImpact of Obesity on the Risk for Polycystic Ovary Syndrome
Yildiz, B. O., Knochenhauer, E. S., & Azziz, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1834 · Cited by 401 · cited 1×
“half of patients are overweight/obese [3, 4].”
Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276 · cited 8×
“[26] Some concerns Some concerns Low risk Low risk Low risk Some concerns Jensterle Sever et al.”
BackgroundMethodInfluentialSalamun, V., Jensterle, M., Janez, A., & Vrtacnik Bokal, E. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0175 · Cited by 204 · cited 4×
“2mg QD) combined with MET (1000mg BID) in the two RCTs [27, 31], and exenatide (10 μg BID) combined with MET (1000mg BID) in one RCTs [26].”
BackgroundResultInfluentialPolycystic ovary syndrome, adipose tissue and metabolic syndrome
Delitala, A. P., Capobianco, G., Delitala, G., Cherchi, P. L., & Dessole, S. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4429-2 · Cited by 159 · cited 1×
“Abdominal obesity is extremely harmful to PCOS patients and hence waist circumference reduction is also an important indicator for evaluating the antiobesity effects of these two medicines [38].”
BackgroundFruzzetti, F., Perini, D., Russo, M., Bucci, F., & Gadducci, A. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1236078 · Cited by 135
Jensterle, M., Kravos, N. A., Pfeifer, M., Kocjan, T., & Janez, A. (2015) · Hormones · doi:10.1007/bf03401383 · Cited by 117 · cited 1×
“[28] Some concerns Some concerns Low risk Low risk Low risk Some concerns Jensterle et al.”
BackgroundJensterle, M., Salamun, V., Kocjan, T., Vrtacnik Bokal, E., & Janez, A. (2015) · Journal of Ovarian Research · doi:10.1186/s13048-015-0161-3 · Cited by 103
Polycystic Ovary Syndrome, Obesity, and Pregnancy
Joham, A., Palomba, S., & Hart, R. (2016) · Seminars in Reproductive Medicine · doi:10.1055/s-0035-1571195 · Cited by 96
Jensterle, M., Kravos, N. A., Goričar, K., & Janez, A. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0155-9 · Cited by 93
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Lyseng-Williamson, K. A. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00826-0 · Cited by 87 · cited 1×
“*e benefits of GLP1RAs are the lower risk of hypoglycemia and cardiovascular disease than other antidiabetic agents [17, 18].”
BackgroundJensterle, M., Kocjan, T., Kravos, N. A., Pfeifer, M., & Janez, A. (2015) · Endocrine Research · doi:10.3109/07435800.2014.966385 · Cited by 86 · cited 1×
“Compared with MET, GLP-1RAs can significantly reduce body weight, abdominal obesity and improve the indicators of glucose and lipid metabolism in PCOS patients [20, 21].”
BackgroundKuchenbecker, W. K. H., Groen, H., van Asselt, S. J., Bolster, J. H. T., Zwerver, J., Slart, R. H. J., vd Jagt, E. J., Muller Kobold, A. C., Wolffenbuttel, B. H. R., Land, J. A., et al. (2011) · Human Reproduction · doi:10.1093/humrep/der229 · Cited by 76 · cited 1×
“*erefore, body weight control of PCOS patients can not only improve the insulin resistance and reproductive function but also reduce the risk of the above diseases [10, 11].”
BackgroundKahal, H., Aburima, A., Ungvari, T., Rigby, A. S., Coady, A. M., Vince, R. V., Ajjan, R. A., Kilpatrick, E. S., Naseem, K. M., & Atkin, S. L. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0005-6 · Cited by 74 · cited 1×
“Niafar’s study considered a case-control study [40], while all selected studies in our analysis were RCTs.”
BackgroundSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74 · cited 1×
“*ey can not only inhibit appetite and increase satiety by binding to receptors in the hypothalamus but also delay gastric emptying and inhibit intestinal peristalsis through binding to receptors in gastrointestinal track [34, 35].”
BackgroundA systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries
Niafar, M., Pourafkari, L., Porhomayon, J., & Nader, N. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3976-7 · Cited by 66 · cited 2×
“Inconsistent with our results, Niafar’s meta-analysis showed that waist circumference was not significantly reduced in PCOS women after liraglutide treatment when compared with the control group [39].”
ResultPani, A., Gironi, I., Di Vieste, G., Mion, E., Bertuzzi, F., & Pintaudi, B. (2020) · International Journal of Endocrinology · doi:10.1155/2020/6276187 · Cited by 38
Cited by
Obesity and the kidney: mechanistic links and therapeutic advances
Yau, K., Kuah, R., Cherney, D. Z. I., & Lam, T. K. T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00951-7 · Cited by 91
“Greater weight loss is observed in patients treated with metformin and GLP1RA combination therapy than in those treated with metformin monotherapy 159 , while metformin and dapagliflozin together elicit greater weight loss than either treatment alone in individuals with obesity and metabolic…”
Goldberg, A., Graca, S., Liu, J., Rao, V., Witchel, S. F., Pena, A., Li, R., Mousa, A., Tay, C. T., Pattuwage, L., et al. (2024) · Obesity Reviews · doi:10.1111/obr.13704 · Cited by 59
Jensterle, M., Herman, R., & Janež, A. (2022) · Biomedicines · doi:10.3390/biomedicines10081989 · Cited by 50
LeBlanc, E. S., Brooks, N., Davies, M., & Chatterjee, R. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae655 · Cited by 11
Metadata
- Authors
- Lyu, X., Lyu, T., Wang, X., Zhu, H., Pan, H., Wang, L., Yang, H., & Gong, F.
- Venue
- International Journal of Endocrinology
- Publisher
- Wiley
- Published
- 2021-02-13
- Volume
- 2021
- Pages
- 1-11
- ISSN
- 1687-8337 (ISSN-L)
- 1687-8345
- OpenAlex
- W3132808481
- Cited by
- 33
- References
- 25
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.